Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Azintuxizumab vedotin for R/R multiple myeloma

Ravi Vij • 6 Apr 2020
Multiple Myeloma Antibodies Azintuxizumab vedotin

Ravi Vij, MD, MBA, Washington University Medical School, St Louis, MO, talks on the antibody-drug conjugate azintuxizumab vedotin (ABBV-838) that targets SLAMF7/CS1 in the treatment of patients with relapsed and refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ravi Vij

MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
2:48
MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myeloma
Ravi Vij • 11 Dec 2023
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
2:26
Lenalidomide as post-autoSCT maintenance therapy for multiple myeloma
Ravi Vij • 11 Dec 2023
Updated safety and efficacy results of ABBV-383, a novel BsAb, in patients with R/R multiple myeloma
3:23
Updated safety and efficacy results of ABBV-383, a novel BsAb, in patients with R/R multiple myeloma
Ravi Vij • 11 Dec 2023
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
2:35
Resistance to immunotherapy in multiple myeloma: mechanisms & monitoring
Ravi Vij • 12 Dec 2022

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Ravi Vij • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Ravi Vij • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Ravi Vij • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Ravi Vij • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals